Track Conduit Pharmaceuticals's other current liabilities ($290M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (March 2026), CDT shows a other current liabilities of $290M. That compares with $280M in the prior-year period — up 2.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CDT's other current liabilities is now $290M (was $280M) — a 2.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Conduit Pharmaceuticals is outperforming or lagging.
Tracking CDT's other current liabilities over time shows whether Conduit Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $290M That compares with $280M in the prior-year period — up 2.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this other current liabilities page, Stockcircle has Conduit Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $290M) with ownership activity and broader fundamentals.